SCHEMBL6178075

SCHEMBL6178075

N#Cc1cccc(Cn2ccc3ccc(Br)cc3c2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 1/20 0.46
PIK3CA P42336 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
CYP19A1 P11511 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
DDR1 Q08345 2/20 0.42
PSMB1 P20618 2/20 0.42
PSMB5 P28074 2/20 0.42
ADORA2A P29274 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6181448 0.86 DDR1 (0.44) PIK3R1PIK3CACYP19A1CYP11B1CYP11B2
SCHEMBL6243270 0.83 CYP19A1 (0.44) PIK3R1PIK3CAL3MBTL1CYP19A1CYP11B1
SCHEMBL31241086 0.82 PSMB1 (0.48) PSMB1PSMB5ALDH1A1MEN1KMT2A
SCHEMBL13392342 0.82 PSMB1 (0.48) PSMB1PSMB5ALDH1A1MEN1KMT2A
SCHEMBL6171027 0.81 EGLN1 (0.53) PSMB1PSMB5ALDH1A1KDM4EMAPT
SCHEMBL6167939 0.81 MAPK14 (0.52) L3MBTL1CYP11B1CYP11B2PSMB1PSMB5
SCHEMBL5697240 0.81 MMP13 (0.57) L3MBTL1CYP19A1CYP11B1CYP11B2DDR1
SCHEMBL25853598 0.80 L3MBTL1 (0.53) PIK3R1PIK3CAL3MBTL1CYP19A1CYP11B1
SCHEMBL6169682 0.79 MAPT (0.55) PIK3CADDR1PSMB1PSMB5ALDH1A1
SCHEMBL28061819 0.76 HDAC3 (0.47) CYP19A1CYP11B1CYP11B2ALDH1A1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1530472-A1 ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-05-18 EP disclosed
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2004-03-04 US disclosed
WO-2004014379-A1 ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors MMP1, MMP13, MMP9 PIK3R1 1889/4885PIK3CA 2647/4885L3MBTL1 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.